news-medical.net
Study finds potential biomarker for joint inflammation in Crohn's disease
The study points to a specific gut microbe, Mediterraneibacter gnavus, that may be linked to joint inflammation in people with Crohn's disease. If confirmed, a microbial biomarker could help identify who is at risk for spondyloarthritis and guide future research into targeted therapies.
Adults with Crohn's disease (especially those with joint symptoms), gastroenterologists, rheumatologists, and researchers studying the gut microbiome and extraintestinal manifestations of IBD.
What To Know
Researchers at Weill Cornell analyzed stool and blood samples from people with Crohn's disease with and without spondyloarthritis to look for bacteria targeted by circulating IgG antibodies.
They found that the gut bacterium Mediterraneibacter gnavus was more often coated with IgG in people with Crohn's plus peripheral or axial spondyloarthritis compared with Crohn's without joint inflammation and healthy controls. The level of IgG coating correlated with joint disease activity scores in the study cohort. The authors suggest M.
gnavus could be a biomarker for joint inflammation in Crohn's disease and note future work could try to identify specific bacterial epitopes that trigger immune responses, with a long-term goal of altering that response. The study is reported in Gut Microbes and uses a modest-sized, well-characterized patient cohort from a single center.
This is early-stage research identifying associations between the microbiome and immune responses in Crohn's-related joint disease; it does not establish causation or change current treatment recommendations.
This report describes an observational study identifying associations between IgG-coated gut bacteria and joint inflammation; it does not prove causation. The cohort is from a single center and findings will need replication and mechanistic follow-up before clinical use. The original article in Gut Microbes is the primary source for study details.
